- Home
- TXMD vs NNVC Comparison
TXMD vs NNVC Comparison
Compare TXMD & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | NNVC |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 21.2M |
| IPO Year | 2012 | 2008 |
Fundamental Metrics
Financial Performance| Metric | TXMD | NNVC |
|---|---|---|
| Price | $2.02 | $1.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | 10.00 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $212.00 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.98 | $0.85 |
| 52 Week High | $2.95 | $2.23 |
Technical Indicators
Market Signals| Indicator | TXMD | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 55.03 |
| Support Level | $2.10 | $1.35 |
| Resistance Level | $2.29 | $1.87 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 80.83 | 43.51 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.